A phase II study of first-line single agent of gefitinib in patients (pts) with stage IV non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Suzuki, R [1 ]
Hasegawa, Y [1 ]
Baba, K [1 ]
Saka, H [1 ]
Saito, H [1 ]
Taniguchi, H [1 ]
Yamamoto, M [1 ]
Matsumoto, S [1 ]
Kato, K [1 ]
Shimokata, K [1 ]
机构：
[1] Cent Japan Lung Study Grp, Nagoya, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：640S / 640S
页数：1
相关论文
共 50 条
  • [41] Phase II trial of gemcitabine and cisplatin as first-line treatment of advanced non-small cell lung cancer (NSCLC).
    Lee, NS
    Byun, JH
    Bae, SB
    Kim, CK
    Lee, KT
    Park, SK
    Park, KK
    Won, JH
    Hong, DS
    Park, HS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 701S - 701S
  • [42] Vinorelbine plus oxaliplatin in unfit patients (pts) with stage IV non-small cell lung cancer (NSCLC)
    Mir, O.
    Alexandre, J.
    Ropert, S.
    Durand, J.
    Martin, I.
    Montheil, V.
    Goldwasser, F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] SPIROMETRY IN PATIENTS WITH STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC)
    Mendis, R.
    McDonald, C. F.
    John, T.
    O'Donoghue, F. J.
    White, S. C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S75 - S75
  • [44] Erlotinib in First-line Therapy for Non-small Cell Lung Cancer: A Prospective Phase II Study
    Choi, Dae Ro
    Lee, Dae Ho
    Choi, Chang-Min
    Kim, Sang-We
    Suh, Cheolwon
    Lee, Jung-Shin
    [J]. ANTICANCER RESEARCH, 2011, 31 (10) : 3457 - 3462
  • [45] A phase II first-line study of gemcitabine, carboplatin, and bevacizumab (GCB) in advanced (adv) stage non-squamous non-small cell lung cancer (NSCLC)
    Krupitskaya, Y.
    Ganjoo, K.
    Lavori, P. W.
    Kumar, A.
    Clement-Duchene, C.
    Zhao, G.
    Padda, S.
    San Pedro-Salcedo, M.
    Wakelee, H. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer
    Clement-Duchene, Christelle
    Krupitskaya, Yelena
    Ganjoo, Kristen
    Lavori, Philip
    McMillan, Alex
    Kumar, Atul
    Zhao, Gary
    Padda, Sukhmani
    Zhou, Lisa
    San Pedro-Salcedo, Melanie
    Colevas, A. Dimitrios
    Wakelee, Heather A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (11) : 1821 - 1825
  • [47] A phase II trial of weekly paclitaxel (P) and gefitinib (G) in patients (pts) with gefitinib-refractory or -resistant non-small cell lung cancer (NSCLC).
    Kasahara, K
    Sone, T
    Kimura, H
    Yoshimoto, A
    Araya, T
    Iwasa, KI
    Shirasaki, H
    Shintani, H
    Fujimura, M
    Nakao, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 639S - 639S
  • [48] Phase II study of docetaxel and oxaliplatin in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer (NSCLC).
    Raez, L. E.
    Brito, R.
    Kobina, S.
    Perdekamp, M. G.
    Karr, M.
    Santos, E. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] FIRST-LINE ERLOTINIB IN ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Merimsky, O.
    Cheng, A. C.
    Reck, M.
    Au, S. K.
    von Pawel, J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 101 - 102
  • [50] RANDOMISED PHASE II STUDY OF AXITINIB OR BEVACIZUMAB COMBINED WITH PACLITAXEL/CARBOPLATIN (PAC/CARB) AS FIRST-LINE THERAPY FOR PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Twelves, C.
    Chmielowska, E.
    Havel, L.
    Popat, S.
    Swieboda-Sadlej, A.
    Sawrycki, P.
    Bycott, P.
    Niethammer, A.
    De Besi, P.
    Schiller, J. H.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 409 - 409
12345